Recent Updates
Recently added Catalysts
QTRX Positive Sentiment

Quanterix Releases Financial Results for the Third Quarter of 2026

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Quanterix Corporation reported its financial results for Q3 2026, showing a 6.3% sequential revenue growth. This growth comes despite ongoing market challenges. The company noted improvements across all business segments, indicating a positive trend in restoring growth.

Market Sentiment Analysis

POSITIVE FACTORS

  • Higher than expected topline growth reported.
  • Revenues increased by 6.3% sequentially.
  • Sequential improvement across all business segments.

Full Press Release Details

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the third quarter ended September 30, 2026. “We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercia

Frequently Asked Questions

What were Quanterix's Q3 2026 revenue results?

Quanterix reported a 6.3% sequential revenue growth.

How did Quanterix perform despite market conditions?

The company achieved higher than expected topline growth.

What is the focus of Quanterix Corporation?

Quanterix is a leader in precision biomarker science.

What improvements did Quanterix see in Q3 2026?

The company noted sequential improvement across all business segments.

ShareAdd on Google
Tags: QTRX Quanterix financial results biomarker science revenue growth
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$94M liquidity · $2M/mo burn
~52 mo
Minimal dilution risk